We are a profitable and growing company focused on the acquisition, development and commercialization of branded prescription products for specialty physician market segments. Since our inception in 1999, we have successfully funded the acquisition and development of our product portfolio with limited external investment, and have been profitable since 2004. We believe we have significant growth opportunities with our existing product portfolio and we continue to identify and pursue other promising product candidates. Source
No articles found.
Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...
Scopus BioPharma develops small molecule therap...
Allstar Health Brands, Inc., a specialty health care products company, focuses on ...
Allstar Health Brands, Inc., a specialty health...
As of June 30, 2019, Sabraâs investment portfolio included 432 real estate prope...
As of June 30, 2019, Sabraâs investment portf...
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...
Enlivex is a clinical stage immunotherapy compa...
Orgenesis is a vertically-integrated biopharmaceutical company with unique experti...
Orgenesis is a vertically-integrated biopharmac...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
Union Acquisition Corp. II, led by Juan Sartori and Kyle Bransfield, is a Cayman I...
Union Acquisition Corp. II, led by Juan Sartori...
Join the National Investor Network and get the latest information with your interests in mind.